Efficacy and Safety of Direct Oral Anticoagulants for the Treatment of Mural Thrombus
Public ClinicalTrials.gov record NCT04153591. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To describe the prescribing patterns at Methodist Dallas Medical Center (MDMC) for the treatment of newly diagnosed mural thrombus and to determine the efficacy and safety of DOACs apixaban, dabigatran, and rivaroxaban in comparison to warfarin. With limited treatment guideline consensus, minimal evidence to support the use of DOACs for Left Atrial Appendage (LAA) thrombus and Left Ventricular Thrombus (LVT), and a lack of evidence for the use of DOACs in aortic thrombus, further research is warranted to determine the role of DOACs in the treatment of various mural thrombi in comparison to warfarin.
Study identification
- NCT ID
- NCT04153591
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2019
- Primary completion
- Jun 21, 2020
- Completion
- Jun 21, 2020
- Last update posted
- Dec 12, 2021
2019 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Methodist Dallas Medical Center | Dallas | Texas | 75203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Acute Myocardial Infarction trials
Other public records listing Acute Myocardial Infarction. Sorted by last update posted; newest first. Not a recommendation.
- NCT05073419: Arrhythmia Detection After MI Recruiting
- NCT05800951: Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock Active, not recruiting
- NCT04743245: Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard. Recruiting
- NCT05185492: Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock Recruiting
- NCT04573660: Abbott Vascular Medical Device Registry Recruiting
- NCT05701358: Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04153591, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 12, 2021 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04153591 live on ClinicalTrials.gov.